*QARS* (OMIM \#615760) encodes a glutaminyl-tRNA synthetase responsible for linking tRNA with amino acids.^[@R1]^ This aminoacylation is essential for translation of mRNA to proteins.^[@R2]^ *Drosophila* studies have shown that *QARS*-encoded synthetase is crucial for termination of fine branching structures at dendrites and axons during early brain development.^[@R1]^ *qars*^−/−^ zebrafish have smaller eyes and brains, progressive neural cell death, and exhibit uncoordinated movements.^[@R1]^ Humans have 37 genes encoding different aminoacyl-tRNA synthetases. So far, pathogenic variants have been found in more than 22,^[@R3][@R4][@R9]^ including *AARS* (encephalopathy, refractory early-onset epilepsy, microcephaly, growth retardation, and peripheral neuropathy)^[@R10]^ and *VARS* (developmental delay, epileptic encephalopathy, and primary or progressive microcephaly).^[@R4],[@R5]^

*QARS* was first connected to disease in 2014^[@R1]^ in 4 individuals from 2 unrelated families with severe epilepsy of neonatal onset, severe intellectual disability (ID), and progressive microcephaly with cerebral-cerebellar atrophy. They were found to have compound heterozygous variants in *QARS*. Cellular in vitro studies of the disease-associated variants have shown a loss of function of the glutaminyl-tRNA synthetase, probably due to misfolding and aggregation of the protein. Further reports confirmed both nonsense and missense variants in *QARS* as pathogenic.^[@R2],[@R11][@R12][@R15]^ The phenotype has been generally consistent with progressive microcephaly, cerebral atrophy, severe ID, and drug-resistant epilepsy. However, among the 12 published patients, a small subgroup with homozygous deleterious variants seems to display a milder phenotype. With this study, we aimed to further define the clinical spectrum associated with pathogenic *QARS* variants and assess first genotype-phenotype associations.

Methods {#s1}
=======

New patients were ascertained through diagnostic screening of an epilepsy cohort, using the EPIDASD (Epilepsy, Intellectual disability and Autism Spectrum Disorders) gene panel at Amplexa Genetics A/S (NM_005051.2) and whole-genome sequencing performed as part of the Undiagnosed Diseases Program---Western Australia.^[@R16]^ Homozygous variants were reported when present in heterozygous form in \<100 controls and not seen in homozygous form in controls. All findings were confirmed by Sanger sequencing. All variants were detected in heterozygous state in the parents to prove for biallelic variants in the index patients. Further patients were recruited through an international network of clinical geneticists and physicians working with severe epilepsy and GeneMatcher.^[@R17]^ Available cranial MRI data sets were reviewed by a single neuroradiologist (C.R.).

Clinical information including data on phenotype, epilepsy, EEG, neuroimaging, and treatment response was evaluated for all the patients included in the article. Seizures and epilepsy syndromes were classified according to the International League Against Epilepsy.^[@R18],[@R19]^ A PubMed search using the search term "*QARS*" was performed to obtain information on all previously published cases. Additional information was added by the referring physicians on 2 previously reported patients.^[@R1]^

Variants were assumed pathogenic or likely pathogenic, if they were homozygous or compound heterozygous, nonsynonymous, splice site altering, or frameshift changing. Variants were tested with prediction software (PolyPhen-2, SIFT, and MutationTaster) for probable pathogenicity. The gnomAD database was used to check allele frequency in healthy controls. Variants were classified pathogenic or likely pathogenic according to the recommendations for interpretation of sequence variants published by the American College of Medical Genetics and Genomics.^[@R20],[@R21]^

Variants were modeled in silico, based on the crystal structure of the intact human GlnRS at 2.4 Å resolution.^[@R22]^ The model was analyzed using the program COOT.^[@R23]^ Point mutations were introduced in silico using the standard rotamer library of *COOT* and analyzed for the appearance of steric clashes or repulsive forces of side chains. Splice site variants gave an unknown protein product and could not be modeled. Figures were prepared using the program Pymol ([pymol.org](http://www.pymol.org)). Upon request, access to data will be given to those eligible for this.

\(1\) This study was approved by the local ethical authorities of University Hospital Medical Center Leipzig and University Center for Rare Diseases Leipzig. (2) Genetic analysis in the patients reported in this study was performed through diagnostic screening. No additional experiments were performed. For retrospective analysis and genotype-phenotype assessment of genetic and clinical data, approval from the ethical standards committee was received. (3) All legal parents (all patients were minors) provided written informed consent for research. (4) Authorization has been obtained for disclosure (consent-to-disclose) of any recognizable persons in photographs or other information in this article. (5) This study is not included in a public trials registry. Data Availability Statement: All relevant clinical and genetic data of the patients in this study are shared and provided in the article, including supplemental material.

Results {#s2}
=======

We collected a cohort of 22 patients (10 new patients and 12 published patients) from 18 families with recessive pathogenic biallelic variants in *QARS*. The cohort includes 11 female and 11 male patients; mean age at follow-up was 59 months (range 5 months to 10 6/12 years). Of note, patient 2 had a brother with a similar phenotype who died before genetic testing could be performed (for details of the brother, see supplemental data appendix e-1, [links.lww.com/NXG/A199](http://links.lww.com/NXG/A199)). [Table 1](#T1){ref-type="table"} provides clinical, radiographic, and epilepsy characteristics of the new patients (for data on all 22 patients, see supplemental data table e-1, [links.lww.com/NXG/A195](http://links.lww.com/NXG/A195); for epilepsy phenotype, table e-2, [links.lww.com/NXG/A196](http://links.lww.com/NXG/A196)). Two patients (3 and 21) were children of consanguineous parents, 3 patients from 2 families (16, 17, and 18) were Ashkenazi Jews. The others were children of unrelated healthy parents.

###### 

Genetic and clinical data of 10 new patients with biallelic variants in *QARS*

![](NG2019010769t1)
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*QARS*-associated phenotype in the cohort of 22 patients {#s2-1}
--------------------------------------------------------

All patients were born after uncomplicated pregnancies. Microcephaly was present at birth in 65% (11/17 patients) and in all patients with available measurements (19/19 patients) at follow-up (range −2.1 SD to −17.2 SD). Five patients were diagnosed with microcephaly already in utero (1, 2, 7, 8, and 22). Regarding overall growth, 21% (3/14 patients) had short birth length, and 56% (9/16 patients) had short stature at follow-up (range −2.2 SD to −5.6 SD). At follow-up, 13% (2/15) showed dystrophy, and 8 patients were reported with a gastrostomy tube. All patients showed delay of motor and speech development. Seventy-three percent (16/22 patients) had severe developmental delay, and 14% (3/22 patients) had moderate delay. Eighty-five percent (17/20 patients) showed no achievement of unassisted sitting, 86% (18/21 patients) no achievement of unassisted walking, and 90% (18/20 patients) were reported with no speech at follow-up.

Hypotonia was reported in 83% (10/12 patients), mainly initially. Additional features included hypertonia/spasticity in 75% (6/8 patients) and stereotypic movements in 75% (6/8 patients). Ten patients displayed periods of intermittent irritability/extreme agitation, with crying, increased sweating, and involuntary movements. Sixty-seven percent (8/12 patients) were reported with no visual interaction, and 6 patients had nystagmus.

Eighty-six percent (19/22 patients) were reported with seizures. Of 11 patients with epilepsy, EEG data were available. Eighty percent were reported with seizure onset within the first 4 days of life (total range 1st hour of life to 5.5 months). Epilepsy syndrome classification remained difficult due to the high variability of seizure types, duration, frequency, and EEG abnormalities. Often, seizures were reported as frequent and/or long lasting with variable seizure types including focal, multifocal, generalized, and myoclonic seizures. Seven patients had recurrent status epilepticus, some of which lasted several hours. At epilepsy onset, EEG showed various patterns, such as focal, bilateral, multifocal epileptic discharges, hypsarrhythmia, and even a "focal migrating seizure-like" pattern ([Table 1](#T1){ref-type="table"}, e-1, [links.lww.com/NXG/A195](http://links.lww.com/NXG/A195), and e-2, [links.lww.com/NXG/A196](http://links.lww.com/NXG/A196)). At follow-up, seizure semiology had not changed. Twenty-eight percent (5/18 patients) were reported with seizures sensitive to fever or infections, with increased seizure frequency under those circumstances. Several antiepileptic drugs (AEDs) were tried; 2 patients responded partly to vigabatrin, and 1 had a positive response to ketogenic diet. Seventy-nine percent of the patients had pharmacoresistant epilepsy (15/19 patients). Of interest, 27% (6/22 patients) were reported with no seizures or were seizure free at follow-up. Patient 3 and patients 16, 17, and 18 had no epilepsy. Patient 4 only had seizures during a course of meningoencephalitis, and patient 21 was reported with febrile seizures only.^[@R11]^

Cranial MRI was performed in almost all patients (21/22 patients with data). [Figure 1](#F1){ref-type="fig"} displays characteristic neuroimaging features in the patients. Characteristic features include cortical atrophy (89%, 16/18 patients) and cerebellar atrophy (61%, 11/18 patients), cortical structural anomalies (56%, 10/18 patients) including simplified gyral pattern and pachygyria, hypoplasia of the corpus callosum (79%, 15/19 patients), delayed myelination (88%, 15/17 patients), ex vacuo enlargement of internal and external liquor spaces, and widening of subarachnoid spaces (95%, 18/19 patients). No abnormalities of the brain stem were reported. Progressive atrophy is most evident in cranial imaging of patient 2 with almost 9-year timespan to follow-up. In this patient, progressive atrophy is evident in the supratentorial brain regions with reduced white matter bulk and pachygyria and of the corpus callosum, which is described as hypoplastic at age 14 weeks and completely atrophic at age 9 years. One reported patient (patients 21)^[@R11]^ was described with no structural defaults on MRI.

![Spectrum of structural brain anomalies in *QARS*-associated microcephaly\
MRI data sets of the new patients 1 (1a,b), 2 (2a,c at 14 weeks; 2b,d at 9 4/12 years), 3 (3a at 6 years; 3b,c,d at 10 years), 5 (5a,b at 27 months), 7 (7a,b at 5 weeks), 8 (8a,c at 1 week; 8b,d at 19 weeks), and 9 (9a,b). Cortical structural anomalies: axial magnetic resonance (MR) images show generalized atrophic supratentorial cerebral volume loss and enlargement of ventricles with progressive atrophy (2 and 8), severe pachygyria (1, 2, 7, 8, and 9), and moderate pachygyria (3 and 5). Trim and flair sequences in patient 3 (3a,b) demonstrate progressive cerebral demyelination. Corpus callosum: sagittal MR images show a spectrum of anomalies of the corpus callosum with relative thinning (3, 6, 7, and 8) and complete atrophy (2, 2d at follow-up).](NG2019010769f1){#F1}

Additional features included hepatosplenomegaly or elevated liver enzymes in 2 patients and ventricular septum defect, hydronephrosis with unilateral hydroureter, and tracheomalacia as single reports. The patients showed mild facial dysmorphism, including long nose with upturned nose tip, but overall no recognizable dysmorphic facial phenotype ([figure 2](#F2){ref-type="fig"}).

![Photographs of patients 2, 7, 9, and 10\
Patients 2, 7, 9, and 10 show mild facial dysmorphism, including narrow foreheads, as would be expected in children with microcephaly, sparse eyebrows, long nose with upturned tip of the nose, dystopia canthorum, dysconjugate gaze, full cheeks, and downturned corners of the mouth.](NG2019010769f2){#F2}

*QARS* genotype {#s2-2}
---------------

Patients in this cohort were either compound heterozygous (17/22) or homozygous (5/22 patients) for *QARS* variants. Most variants located in the N-terminal domain (NTD) and the catalytic domain (CATD), and only 2 variants located in the anticodon-binding domain (ABD). Three variants were recurrent: the variant p.(Gly45Val) was detected in patient 5 and siblings 13/14, the variant p.(Tyr57His) was seen in 2 pairs of siblings (11/12, 19/20), and the splice variant c.2084+2_2084+3del was seen in patients 6 and 22. Two hot spots were found at position 57 (p.(Tyr57\*), p.(Tyr57Cys), p.(Tyr57His)) and at position 378 (p.(Arg378Cys), p.(Arg378His)). All other variants were single reports ([figure 3](#F3){ref-type="fig"}).

![QARS domains and distribution of variants\
Observed *QARS* variants in a schematic illustration; NTD involved in RNA binding, CATD, and ABD. Novel variants (full arrows), published variants (empty arrows, gray). New and published *QARS* variants are listed in table e-3 ([links.lww.com/NXG/A197](http://links.lww.com/NXG/A197)). Protein Ref Seq NP_005042.1. ABD = anticodon-binding domain; CATD = catalytic domain; NTD = N-terminal domain.](NG2019010769f3){#F3}

In silico models of the effects of the variants at the protein level were performed (figure e-1, [links.lww.com/NXG/A198](http://links.lww.com/NXG/A198)). In patient 1, p.(Arg67Trp), a surface variant, may interrupt so far unknown interactions, for instance with protein ligands. The crystal structure of this variant is unknown. The variant p.(Gln461Argfs\*43) truncates QARS, and thus, the protein lacks part of the CATD and the entire ABD, making tRNA binding impossible. For patient 2, the variant p.(Arg378Cys) is involved in stabilizing the fold of the loop in the connecting peptide 1 (CP1) domain, which is involved in interaction with tRNA. This amino acid replacement of arginine to cysteine likely causes minor folding or interaction defects in the CP1 domain. In the variant p.(Arg523\*), the ABD is missing, which affects tRNA binding. In patient 3, the same p.(Arg378His) change observed as in patient 2 was detected in homozygous state, causing minor folding or interaction defects in the CP1 domain. For patient 4, the variant p.(Glu459Asnfs\*45) truncates QARS, causing it to lack part of CATD and the entire ABD, and tRNA binding is abolished, resulting in a clear loss of function. The p.(Tyr435Cys) variant is involved in a number of hydrophobic interactions and hydrogen bonds stabilizing the fold of the surface loop at the border between CP1 domain and CATD, which are involved in interaction with tRNA. Replacement of tyrosine by cysteine likely affects folding and hence tRNA binding. In patient 5, p.(Gly45Val) is a surface variant that may interrupt other, yet unknown, interactions, for instance with protein ligands. The NTD fold might be locally affected.^[@R22]^ In patient 6, the variant p.(Arg265Cys) is located in the interface between NTD, CATD and the Hinge domain. Local structural rearrangement may be the consequence of this variant. For patient 7, the p.(Gly14Ser) variant is unlikely to affect folding or tRNA interaction; however, as it is a surface variant, it may interrupt other still unknown interactions, possibly with protein ligands, as is the case with p.(Gly45Val). The variant p.(Arg525Trp) might result in a changed orientation of ABD and thus affect tRNA binding. For patient 8, the variant p.(Arg524Trp) is expected to lead to full protein expression, but misfolding and changed orientation of ABD may affect tRNA binding. The variant p.(Arg690Cys) may affect the local folding of human GlnRS. However, how this influences tRNA binding is unknown. In patient 9, variant p.(Tyr57\*) is located in the N-terminal part of the NTD, which causes only the first third of the domain to be expressed and a large C-terminal portion missing. No functional protein is expressed. Regarding the variant p.(Tyr57Cys), it is unlikely for a single amino acid variation to cause drastic conformational changes, but according to Ognjenović et al.,^[@R22]^ variants in the NTD affect tRNA positioning and binding and decrease catalytic activity and stability of human GlnRS. These mutants will be unable to form a productive complex with tRNAGln. In patient 10, the variant p.(Arg403Trp) is located in the CP1 domain. The hydrophilic side chain of arginine is involved in a number of hydrogen bonds with the surrounding residues, stabilizing the fold of the CP1 domain. Its replacement by the larger aromatic tryptophan will cause local disturbance of interactions and likely misfolding. This might affect interaction with potential protein ligands. The surface variant p.(Ala2Thr) in the NTD is unlikely to affect fold or tRNA interaction but may interrupt other, yet unknown, interactions.

We also modeled previously published variants. In siblings 11 and 12,^[@R1]^ the variant p.(Tyr57His) was described for patient 9. The variant p.(Arg515Trp) is expected to lead to full protein expression, but folding defects and changed orientation of ABD may affect tRNA binding. In patients 16, 17, and 18,^[@R14]^ the homozygous p.(Val476Ile) variant, located in the CATD, may cause local disturbance of interactions and minor misfolding. In addition, the p.(Gly353Val) variant in patient 21 is likely to cause minor effects on folding, which might affect protein-protein interaction. This variant is located in the solvent exposed loop of the CP1 domain.

Discussion {#s3}
==========

In this work, we expand the known population of 12 individuals with biallelic pathogenic variants in *QARS* by 10 new patients and further delineate the *QARS*-associated clinical spectrum. Although most patients show a homogeneous phenotype, some patients (mainly the patients with a homozygous variant) display a milder presentation with better outcome.

Microcephaly was present in utero, at birth, or became evident during the early infantile period in all patients, being extremely severe with up to −17 SD and progressive. It seems that progression is worst in early infancy. Patients below or around 2 years of age have progression of their microcephaly with 4 to 7 SD per year. Older patients have a moderate progression, albeit severe, around 2 to 4 SD per year. Part of this, or all, will probably be due to the fact that the normal brain grows the most during early childhood. In addition to microcephaly, some dysmorphic facial features can be present, including a long nose with upturned nose tip and dystopia canthorum. Developmental delay is evident in all patients, with severe delay in the patients with compound heterozygous variants (except patients 4 and 5) and mild to moderate delay in those with homozygous variants who also display mild progression in their speech and motor development, with some even learning to walk (patient 16 at age 10 years). Neurologically, hypotonia is a common feature, not only in the neonatal period but also in childhood. Furthermore, feeding difficulties seem to be a common problem, with several patients requiring gastroenteral tube feeding. Of interest periods of irritability or agitation with autonomic features were reported in several patients. The background for these episodes is not clarified, and might be underestimated, because those who displayed them were in their early childhood, and the mean age of this cohort is still fairly low. Agitation is a cluster of behaviors that can be found in a number of psychiatric disorders^[@R24]^ and have overlap with hyperactivity and restlessness. The agitation described in the patients of this cohort could be classified as aggressive physical and verbal. The underlying mechanisms of agitation are not yet clarified, but it is suggested that agitation runs through the same neurologic systems as movement disorders. This could be part of the explanation of why patients with pathogenic *QARS* variants experience these agitated episodes.

Epilepsy associated with deleterious variants in *QARS* is in most cases extremely severe. Most patients have seizure onset within the first few days and often within the first few hours of life. Focal seizures seem to be the predominant seizure type, often described as multifocal, and often, seizure frequency is extremely high. Patients, who experienced status epilepticus, often had very long status episodes lasting several hours. At follow-up, epilepsy remained relentless and uncontrolled despite of different combinations of AEDs. As of now, the mechanisms underlying an epilepsy so severe are unknown, but a crucial function of the glutaminyl-tRNA synthetase can be postulated, and the in silico modeling indicated that most of the variants will damage the protein folding and expression. Furthermore, follow-up times are very short, and thus, developmental evolution in adolescence and adulthood in affected patients is still unknown.

Our study shows that some patients with *QARS* deleterious variants had a milder phenotype compared with the overall cohort. Patient 3 is microcephalic (−2.4 SD at 10 6/12 years) and severely disabled but does not have epilepsy or experienced seizures. Patient 4 is microcephalic (−3.1 SD at 5 1/12 years), but shows only mild ID. He has gained the ability to walk and even speaks short sentences, albeit expressive language is delayed. Furthermore, he only experienced seizures as part of an episode of meningoencephalitis and has been seizure free since. Patient 5 is microcephalic (−2.4 SD at 4 6/12 years), but did not have seizure onset before age 5.5 months, and so far, the phenotype looks milder than expected with a seizure frequency of 1 seizure in 3 months at follow-up. He is currently classified with mild ID. Of interest, one of his variants only shows minor structural changes by in silico modeling, which may help explain the milder phenotype. Patient 21 is reported to be microcephalic (no measurements available) and has experienced febrile seizures only that resolved spontaneously. His MRIs were reported to be normal, and he was classified with mild ID.^[@R11]^ His homozygous variant showed only minor effects on folding when modeled, which could support the milder outcome. The variant is seen one time as heterozygous in gnomAD. Siblings 16 and 17, and patient 18, all Ashkenazi Jews, have mild to moderate ID and have not developed seizures at the last follow-up (at age 10 years, 7 6/12 years, and 3 years, respectively).^[@R14]^ It should be noted that the heterozygous form of the variant p.(Val476Ile) has a high incidence (allele count 443) in gnomAD, and furthermore, one healthy homozygous carrier is listed, which might suggest that this variant could be a benign polymorphism. However, functional analyses in the original study^[@R14]^ showed a 67% decrease in QARS activity, and in silico modeling performed in this study supports a disease-causing function of the variant. Thus, we classified the variant as "likely pathogenic."^[@R18]^ One can speculate that ethnicity-based differences might attribute to the differential phenotypic expression as the homozygous carrier listed in gnomAD is of south Asian origin.

Of note, 5 of the above discussed 7 patients with a milder phenotype carry a homozygous pathogenic missense variant in *QARS*. Thus, it somehow seems that homozygosity is protective for the risk of developing epilepsy. This phenomenon has not been seen in the other bifunctional tRNA synthetase *KARS*.^[@R25]^ However, it could be speculated that harboring compound heterozygous variants is worse because it interferes with protein building in two different spots compared with homozygous variants that alter the protein in a milder and alike way. Why patients 4 and 5, with compound heterozygous variants, also display a less severe phenotype remains unknown. Another explanation might be that compound heterozygosity with one protein truncated (null allele) is more deleterious and that homozygous truncating variants in *QARS* are in fact lethal. Therefore, viable homozygous missense variants may be hypomorphic variants, which result in a milder phenotype compared with compound heterozygous variants with one null allele and another hypomorphic allele.

In most patients with pathogenic variants in *QARS*, the clinical picture is uniform and consists of the triad of primary or secondary progressive microcephaly, moderate or severe ID, and severe pharmacoresistant epilepsy. However, our cohort shows that the phenotype is broader than expected with milder phenotypes in some patients. Nonetheless, the presence of the core triad---microcephaly, developmental disability, and early-onset refractory epilepsy---in a young child should elicit a search for biallelic variants in *QARS*, either using a gene panel, because this triad is also common in other epilepsies, or when evaluating exome data. Longer follow-up and the addition of more patients to this exclusive cohort are necessary to gain a better understanding of *QARS* functioning and the associated phenotype.
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